Cite
HARVARD Citation
García‐Carbonero, R. et al. (2017). Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer. Oncologist. pp. 375-e30. [Online].